Cassava Sciences to Present at the H.C. Wainwright Global Life Sciences Conference
Management’s presentation will be available for on-demand viewing through the H.C. Wainwright conference portal beginning at
A webcast of Cassava Sciences’ presentation can be accessed under the ‘Investors’ tab at www.CassavaSciences.com and will be available for replay for 90 days following the event.
About Alzheimer's Disease
Alzheimer’s disease is a progressive brain disorder that destroys memory and thinking skills. Currently, there are no drug therapies to halt Alzheimer’s disease, much less reverse its course. As of 2020, there were approximately 50 million people worldwide living with dementia, a figure expected to increase to 150 million by 2050.1 The annual global cost of dementia is now above
About Simufilam, the Company’s Lead Drug Candidate
Simufilam is a proprietary, small molecule (oral) drug that restores the normal shape and function of altered filamin A (FLNA), a scaffolding protein, in the brain. Altered FLNA in the brain disrupts the normal function of neurons, leading to Alzheimer’s pathology, neurodegeneration and neuroinflammation. The underlying science for simufilam is published in peer-reviewed journals, including
About
Cassava Sciences’ mission is to discover and develop innovations for chronic, neurodegenerative conditions. Over the past 10 years,
For More Information Contact:
eschoen@CassavaSciences.com
(512) 501-2450
1
https://www.alzint.org/about/dementia-facts-figures/dementia-statistics/
Source: Cassava Sciences, Inc.